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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S73Conclusions: Pro-inﬂammatory cytokines are elevated in SF, but not in
serum, immediately after knee ACL injury. SF TNF-a level stay elevated
over the ﬁrst 5 years after ACL injury and this high TNF- a concentration
may contribute to a later development of OA.
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MULTIPLEX ANALYSIS OF OSTEOARTHRITIC SYNOVIAL FLUID:
A COMPARISON OF LUMINEX & MESOSCALE DISCOVERY
C. Jayadev, S. Snelling, A. Price, P. Hulley. Univ. of Oxford, Oxford, United
Kingdom
Purpose: Multiplex immunoassay platforms are indispensible for
biomarker discovery. They allow high-throughput, multiple parallel
analysis of precious small volume samples. The 2 dominant technolo-
gies are Luminex (LX) and MesoScale Discovery (MSD). Neither plat-
form is validated for synovial ﬂuid (SF) analysis. The cross-comparison
of multiplex formats and comparison against the existing gold standard
of ELISA are required to facilitate quality control and guide optimum
assay selection for biomarker discovery. Previous comparison studies in
culture medium and serum/plasma cannot be extrapolated to the
complex biological matrix of SF. The aim was to make a detailed
comparison between LX and MSD platforms during the analysis of
real clinical SF samples from end-stage knee OA.
Methods: SF aliquots from patients with end-stage knee OA (N¼31)
were analysed for the inﬂammatory cytokines IL1b, TNFa, IL6 & IL8
using magnetic-bead LX and MSD multiplex assays. All SF samples
underwent identical collection, processing, storage and hyaluronidase
treatment. Aliquots of an additional SF sample were analysed by each
platform after spiking with 2 known concentrations (high & low) of the
respective assay calibrator. ELISA for IL6 & TNFa was performed on
aliquots from patients previously analysed by the LX (n¼8) and MSD
(n¼11) platforms. The LX and MSD assays were compared for limits of
detection (LOD) & quantiﬁcation (LOQ), spike recovery, and intra-assay
precision. Agreement of cytokine measurements between platforms
and against ELISA was tested by: weighted Deming Regressions (WDR),
concordance correlation coefﬁcient (CCC) for absolute agreement and
intraclass correlation coefﬁcient (ICC) for consistency. P<0.05 was
considered signiﬁcant.
Results: LOD: The MSD platform had a signiﬁcantly lower LOD for all 4
analytes (p<0.01). IL6 & IL8 were >LOD in all samples on both plat-
forms. IL1b & TNFa were >LOD in signiﬁcantly more samples on the
MSD platform: IL1b 81% vs 3% (p<0.001); TNF-a 100% vs 3% (p<0.001).
LOQ: The MSD platform had the lowest LOQ for all 4 analytes, which
was signiﬁcant for all except IL6. Both platforms were able to quantify
IL6 & IL8 in >96% of samples. IL1b & TNFa were not quantiﬁable by the
LX assay compared to 29% (p¼0.003) and 87% (p<0.001) by the MSD
assay. Spike-recovery: Spike recoveries on the MSD platform were
acceptable (10020%) for both concentrations except for the IL6 low-
spike (76.6%). IL6 & IL8 had acceptable recoveries for both spikes
concentrations on the LX platform. Recoveries at either spike concen-
trations were below acceptable for IL1b & TNFa. Intra-assay precision:
The coefﬁcient of variation (CV) for replicate measurements for all
analytes was acceptable (<20%) irrespective of platform. There was no
signiﬁcant difference in median CV between platforms. ELISA valida-
tion: All samples were <LOD on the TNFa ELISA. There was no signiﬁ-
cant systematic or proportional error for IL6 measurements by the
either platform vs ELISA (WDR). There was moderate concordance for
MSD vs ELISA (CCC¼0.901) and poor concordance for LX vs. ELISA
(CCC¼0.768) The consistency of measurements for both platforms vs
ELISA was excellent (>0.90). Cross-platform agreement: There wasTable 1
Cross-sectional ARGS-aggrecan concentrations (nM) in synovial ﬂuid (SF) and serum af
percentiles) with fold difference of the medians compared to REF. P-values, Mann-Whitn
n SF-ARGS fold dif. p-values
REF 21 0.85 (0.57, 1.30) - -
Baseline 51 6.85 (4.41,17.25) 8.1 <0.001
16 weeks 50 1.22 (1.00, 1.89) 1.4 0.005
30 weeks 48 1.10 (0.77, 1.77) 1.3 0.068
1 year 49 0.95 (0.74, 1.32) 1.1 0.349
2 years 85 1.07 (0.79, 1.28) 1.3 0.138
5 years 63 1.01 (0.69, 1.39) 1.2 0.266proportional bias but no systematic bias in IL6 & IL8 measurements
between platforms. The concordance of IL6 (CCC¼0.62) and IL8
(CCC¼0.53) measurements was poor, but the relative agreement was
excellent (ICC>0.95).
Conclusions: The MSD platform is better able to detect and quantify
low-level analytes (IL1b & TNFa) in OA SF samples than LX. There is poor
absolute agreement but excellent relative agreement between plat-
forms. This is most likely due to differences in antibody pairs and
kinetics. Cytokine measurements in OA samples are at best semi-
quantitative and depend on the platform, assay and manufacturer, thus
making comparisons between studies difﬁcult. Biomarker studies
should be consistent and explicit regarding assays.
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LONGITUDINAL CHANGE IN SYNOVIAL FLUID AND SERUM LEVELS OF
ARGS-AGGRECAN OVER 5 YEARS AFTER ANTERIOR CRUCIATE
LIGAMENT INJURY
S. Larsson y, M. Hansson y, R. Frobell y, L.S. Lohmander y,z,
A. Struglics y. yDept. of Orthopaedics, Clinical Sci. Lund, Lund Univ.,
Lund, SWEDEN; zRes. Unit for Musculoskeletal Function and
Physiotherapy, and Dept. of Orthopaedics and Traumatology, Univ. of
Southern Denmark, Odense, Denmark
Purpose: Aggrecanase cleavage at the 373Glu-374Ala bond in the
interglobular domain of aggrecan, releasing N-terminal 374ARGS frag-
ments into synovial ﬂuid (SF-ARGS), is an early key event in arthritis
and joint injuries. We have previously shown that SF-ARGS is associated
with radiographic progression of knee osteoarthritis (OA) as well as
with progression of self-reported pain after meniscectomy. As a part of
a randomized controlled study (KANON), initiated to investigate
structured rehabilitation of anterior cruciate ligament (ACL) injuries
with or without surgical reconstruction, we here report ARGS-aggrecan
levels in SF and in serum over 5 years after ACL injury.
Methods: One hundred and twenty-one subjects (26% women, mean
age 26 years, standard deviation [SD] 4.9 years) with an ACL rupture to
a previously un-injured knee were followed within 3 weeks from
trauma (baseline), at 16 weeks, 30 weeks, 1 year, 2 years and 5 years.
Blood samples were obtained from all subjects and SF was collected
from a subset of subjects (6 subjects had intact series of both SF and
serum samples). Twenty-one knee-healthy individuals (38% women,
mean age 28 years, SD 9.4 years) were used as reference. Levels of
ARGS-aggrecan were measured in all SF and serum samples with an
electrochemiluminescence immunoassay using an anti-aggrecan anti-
body (AHP0022; Invitrogen) for capture, and a monoclonal anti-ARGS
(OA-1) for detection. We used Mann-Whitney rank sum test for
comparison of ARGS-concentrations at different time points compared
to knee-healthy references, and Spearman's rank order correlation for
assessment of correlation, based on Shapiro-Wilk test indicating
skewed distributions at all time points.
Results: Levels of ARGS-aggrecan in SF and serum correlated (Spear-
man's rho¼ 0.245, p< 0.001, n¼ 356) and were overall 10 times higher
in SF than in serum: median nM ARGS in SF (25th and 75th percentiles)
in ACL injured at all time points combined 1.16 (0.83, 1.94) and 0.13
(0.10, 0.17) in serum.
SF-ARGS levels in the ACL injury group were elevated compared to
knee-healthy references at baseline and at 16 weeks after injury, but
after 30 weeks or longer, levels were not signiﬁcantly different from
those observed in the reference group (Table 1). ACL injury serum-ARGS
levels compared to knee-healthy reference level were signiﬁcantly
elevated at baseline but not at any other time point (Table 1).ter ACL injury and in knee-healthy subjects (REF). Values are medians (25th, 75th
ey rank sum tests against uninjured references.
n serum-ARGS fold dif. p-values
19 0.112 (0.075, 0.138) - -
120 0.158 (0.114, 0.198) 1.4 0.002
64 0.134 (0.099, 0.168) 1.2 0.073
63 0.137 (0.107, 0.164) 1.2 0.075
63 0.129 (0.105, 0.157) 1.2 0.148
118 0.125 (0.094, 0.153) 1.1 0.290
115 0.113 (0.091, 0.143) 1.0 0.784
